Get the Stockscreener App
4.4255
20.30%
0.7555
Anavex Life Sciences Corporation stock is traded at $4.4255, with a volume of 4.31M.
It is up +20.30% in the last 24 hours and down -42.96% over the past month.
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
See More
Previous Close:
$3.67
Open:
$3.8
24h Volume:
4.31M
Relative Volume:
1.98
Market Cap:
$394.92M
Revenue:
-
Net Income/Loss:
$-48.17M
P/E Ratio:
-7.764
EPS:
-0.57
Net Cash Flow:
$-37.10M
1W Performance:
+14.38%
1M Performance:
-42.96%
6M Performance:
-43.69%
1Y Performance:
-50.84%
1-Day Range:
$3.80
$4.84
1-Week Range:
$3.62
$4.84
52-Week Range:
$2.86
$14.44
Anavex Life Sciences Corporation Stock (AVXL) Company Profile
Name
Anavex Life Sciences Corporation
Sector
Industry
Phone
844-689-3939
Address
630 5TH AVENUE, NEW YORK
Compare AVXL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVXL
Anavex Life Sciences Corporation
|
4.42 | 327.91M | 0 | -48.17M | -37.10M | -0.57 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.44 | 109.90B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
734.88 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
475.01 | 61.42B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
933.35 | 56.36B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
206.50 | 44.06B | 447.02M | -1.18B | -906.14M | -6.1812 |
Anavex Life Sciences Corporation Stock (AVXL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jun-23-22 | Initiated | Berenberg | Buy |
| Sep-23-21 | Initiated | BTIG Research | Buy |
| Dec-16-20 | Reiterated | H.C. Wainwright | Buy |
| Sep-28-20 | Initiated | Ladenburg Thalmann | Buy |
| Feb-27-20 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-18-19 | Initiated | Janney | Buy |
| May-16-18 | Resumed | Maxim Group | Buy |
| Mar-08-18 | Initiated | ROTH Capital | Buy |
| Feb-13-18 | Reiterated | Maxim Group | Buy |
| Sep-29-17 | Resumed | Noble Financial | Buy |
| Feb-07-17 | Initiated | Noble Financial | Buy |
| Mar-29-16 | Initiated | FBR Capital | Outperform |
View All
Anavex Life Sciences Corporation Stock (AVXL) Latest News
Down 50.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Anavex Life Sciences (AVXL) - Finviz
Can Anavex Life Sciences Corp. (12X1) stock sustain institutional flowsMarket Risk Summary & Technical Buy Zone Confirmations - Newser
Check Out Anavex Life Sciences Corporation (AVXL)’s Trade Data Rather Than the Analysts’ Views - Setenews
What analysts say about Anavex Life Sciences Corp stockEarnings Miss Alerts & Superior Capital Trading - earlytimes.in
Why Anavex Life Sciences Corp. stock could rally in 2025July 2025 Sector Moves & Low Risk High Reward Ideas - BỘ NỘI VỤ
D. Boral Capital Reaffirms Buy Rating for Anavex Life Sciences (NASDAQ:AVXL) - Defense World
Anavex Life Sciences’ (AVXL) Buy Rating Reiterated at D. Boral Capital - Defense World
D. Boral Capital Reiterates Buy Rating for Anavex Life Sciences (NASDAQ:AVXL) - Defense World
Anavex Life Sciences (NASDAQ:AVXL) Given Buy Rating at D. Boral Capital - Defense World
Anavex Life Sciences And 2 Other Promising Penny Stocks To Watch - Yahoo Finance
Anavex (NASDAQ: AVXL) to present blarcamesine Phase IIb/III Alzheimer’s results at CTAD - Stock Titan
Anavex Life Sciences Corp (AVXL) Q4 2025 Earnings Call Highlights: Strong Cash Position and ... - Yahoo Finance
Anavex Life Sciences Corp. Reports Earnings Results for the Fourth Quarter and Full Year Ended September 30, 2025 - MarketScreener
Anavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results and Provides Business Update - MarketScreener
Anavex Life Sciences (NASDAQ: AVXL) Quarter 2025 Reports $102.6M, Three-Year Runway - Stock Titan
You might want to take a look at Anavex Life Sciences Corporation (AVXL) now - Setenews
Will Anavex Life Sciences Corp. stock rally after Fed decisions2025 Breakouts & Breakdowns & Free Long-Term Investment Growth Plans - newser.com
Can Anavex Life Sciences Corp. stock maintain operating marginsWeekly Trade Review & Detailed Earnings Play Alerts - newser.com
How Anavex Life Sciences Corp. (12X1) stock trades after rate cuts - newser.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp.AVXL - cnhinews.com
Anavex Life Sciences Corp. to Release Fiscal Year End Financial Results on November 25, 2025 - Quiver Quantitative
Anavex Life Sciences to Announce Fiscal 2025 Fourth Quarter Financial Results on Tuesday, November 25, 2025 - MarketScreener
Anavex Life Sciences (Nasdaq: AVXL) to Report Fiscal 2025 Results on Nov. 25 - Stock Titan
A significant driver of top-line growth: Anavex Life Sciences Corporation (AVXL) - Setenews
Why Anavex Life Sciences (AVXL) Is Down 43.8% After EMA Setback for Lead Alzheimer’s Drug - Yahoo Finance
Can Anavex Life Sciences Corp. stock deliver strong Q4 earnings2025 Volatility Report & Real-Time Buy Zone Alerts - newser.com
Is Anavex Life Sciences Corp. stock resilient to inflationWeekly Investment Recap & Entry Point Confirmation Alerts - newser.com
Will Anavex Life Sciences Corp. (12X1) stock rise with strong economyJuly 2025 Opening Moves & Pattern Based Trade Signal System - newser.com
Anavex Life Sciences Shares Plummet Following EU Regulatory Setback - StocksToTrade
Anavex Life Sciences Stock Plummets Amid Regulatory Hurdles - StocksToTrade
How strong is Anavex Life Sciences Corp. stock revenue growthQuarterly Trade Review & Consistent Income Trade Ideas - newser.com
Will Anavex Life Sciences Corp. (12X1) stock deliver compounding returns2025 Dividend Review & Technical Entry and Exit Alerts - newser.com
D. Boral Capital Maintains Anavex Life Sciences (AVXL) Buy Recommendation - Nasdaq
Can Anavex Life Sciences Corp. stock attract ESG capital inflowsM&A Rumor & Growth Oriented Trade Recommendations - newser.com
Anavex Life Sciences Corp. (AVXL) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Anavex Life Sciences (NASDAQ:AVXL) Reaches New 12-Month LowHere's Why - MarketBeat
Real time breakdown of Anavex Life Sciences Corp. stock performance2025 Macro Impact & Step-by-Step Trade Execution Guides - newser.com
Micron Tech, Netflix among market cap stock movers on Friday By Investing.com - Investing.com UK
Micron Tech, Netflix among market cap stock movers on Friday - Investing.com
Anavex Life Sciences Crashes as EMA Setback Sparks Doubts on Lead Alzheimer Drug - Investing.com
Anavex Life Sciences Corp. Provides Regulatory Update on Blarcamesine for Early Alzheimer's Disease - MarketScreener
Anavex Life Sciences Falls in Premarket Trading After Alzheimer's Drug Receives EU Regulatory Setback - MarketScreener
Anavex Faces CHMP Setback for Alzheimer’s Drug - MSN
Anavex Life Sciences Plans Re-examination Request Following CHMP Feedback and FDA Meeting on Alzheimer's Disease Trial Results - Quiver Quantitative
Anavex (NASDAQ: AVXL) to seek CHMP re-exam; formal opinion expected in December - Stock Titan
Morning Market Movers: CDTX, BCG, IVVD, TSSI See Big Swings - RTTNews
Anavex Life Sciences (AVXL) Stock Plunges After EMA Issues Negative Trend Vote on Alzheimer’s Drug - ts2.tech
Anavex Stock Just Logged Its Worst Selloff In 2 Years — What Does EMA’s Oral Explanation Week Mean For Its Alzheimer’s Drug? - Stocktwits
Anavex drops 11% as Martin Shkreli says the pharma is his next short - Seeking Alpha
Ready to Jump After Recent Trade: Anavex Life Sciences Corporation (AVXL) - Setenews
Why Anavex Life Sciences Corp. (12X1) stock could be next leaderMarket Sentiment Review & Comprehensive Market Scan Reports - newser.com
Anavex Life Sciences Corporation Stock (AVXL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Anavex Life Sciences Corporation Stock (AVXL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Thomas Steffen | Director |
Jun 05 '25 |
Option Exercise |
1.76 |
50,000 |
88,000 |
55,000 |
| MISSLING CHRISTOPHER U | President and CEO |
Mar 24 '25 |
Option Exercise |
0.92 |
500,000 |
460,000 |
1,750,210 |
0.50%
0.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):